Contact
searchSearch
HMP Global
Login

Interactive Features

Quiz
Autologous Hematopoietic Stem Cell Transplant for Ph-Negative ALL
05/27/2025
In a retrospective study assessing autologous hematopoietic stem cell transplantation for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, which patient subgroup demonstrated superior leukemia-free survival at 5...
In a retrospective study assessing autologous hematopoietic stem cell transplantation for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, which patient subgroup demonstrated superior leukemia-free survival at 5...
In a retrospective study...
05/27/2025
Oncology
Quiz
Efficacy of Inaticabtagene Autoleucel for B-ALL
05/05/2025
What was the overall response rate observed at month 3 following treatment with inaticabtagene autoleucel in a phase 2 trial among patients with R/R B-cell acute lymphoblastic leukemia?
What was the overall response rate observed at month 3 following treatment with inaticabtagene autoleucel in a phase 2 trial among patients with R/R B-cell acute lymphoblastic leukemia?
What was the overall response...
05/05/2025
Oncology
Quiz
Inaticabtagene Autoleucel Therapy for R/R B-ALL
04/21/2025
Regarding the durability of remission achieved with inaticabtagene autoleucel therapy among patients with R/R B-ALL in a phase 2 trial, what was the median duration of remission reported?
Regarding the durability of remission achieved with inaticabtagene autoleucel therapy among patients with R/R B-ALL in a phase 2 trial, what was the median duration of remission reported?
Regarding the durability of...
04/21/2025
Oncology
Quiz
Efficacy of Imatinib vs Dasatinib Prophylaxis Among Patients With Philadelphia-Positive ALL Following ASCT
04/02/2024
04/02/2024
Oncology
Quiz
R/R Pre-B ALL Treatment With Mini-Hyper CVD Chemotherapy Plus Inotuzumab Ozogamicin With or Without Blinatumomab
08/01/2023
True or False: A treatment regimen of low-intensity mini-hyper CVD plus inotuzumab and blinatumomab demonstrated improved survival outcomes among patients with R/R Philadelphia chromosome-negative CD22-positive pre-B ALL.
True or False: A treatment regimen of low-intensity mini-hyper CVD plus inotuzumab and blinatumomab demonstrated improved survival outcomes among patients with R/R Philadelphia chromosome-negative CD22-positive pre-B ALL.
True or False: A treatment...
08/01/2023
Oncology
Quiz
Quiz: Use of Inotuzumab Ozogamicin Induction Therapy for De Novo Acute B-Lymphoblastic Leukemia
03/01/2023
True or False: 3 cycles of inotuzumab ozogamicin induction therapy showed promising remission rates in patients aged >55 years with de novo acute B-lymphoblastic leukemia, according to findings from a recent trial.
True or False: 3 cycles of inotuzumab ozogamicin induction therapy showed promising remission rates in patients aged >55 years with de novo acute B-lymphoblastic leukemia, according to findings from a recent trial.
True or False: 3 cycles of...
03/01/2023
Oncology
Quiz
Use of Blinatumomab During Consolidation for High-Risk Ph-Negative B-Cell Precursor ALL
03/01/2023
True or False: The use of blinatumomab during consolidation for high-risk Philadelphia chromosome negative B-Cell precursor acute lymphoblastic leukemia was associated with reduced relapse rates, according to findings from a recent trial.
True or False: The use of blinatumomab during consolidation for high-risk Philadelphia chromosome negative B-Cell precursor acute lymphoblastic leukemia was associated with reduced relapse rates, according to findings from a recent trial.
True or False: The use of...
03/01/2023
Oncology
Quiz
Quiz: ASCT From Matched Sibling Donors vs Matched Unrelated Donors in Adult High-Risk ALL
10/05/2022
True or False: Allogeneic hematopoietic stem cell transplantations from matched sibling donors and matched unrelated donors yielded similar long-term outcomes for patients with BCR-ABL-negative ALL.
True or False: Allogeneic hematopoietic stem cell transplantations from matched sibling donors and matched unrelated donors yielded similar long-term outcomes for patients with BCR-ABL-negative ALL.
True or False: Allogeneic...
10/05/2022
Oncology
Quiz
Quiz: Complete Remission Rate Among Patients With R/R B-Cell ALL With Anti-CD19 CAR T-Cell Therapy
08/23/2022
True or false: The complete remission rate was higher among patients with relapsed/refractory B-cell ALL with lower (rather than with higher) tumor burden receiving treatment with anti-CD19 CAR T-cell therapy.
True or false: The complete remission rate was higher among patients with relapsed/refractory B-cell ALL with lower (rather than with higher) tumor burden receiving treatment with anti-CD19 CAR T-cell therapy.
True or false: The complete...
08/23/2022
Oncology
Quiz
Quiz: Patients With ALL Are More Likely to Receive Salvage Chemotherapy After Treatment With Which Prior Therapy?
08/05/2022
True or False: Findings from the phase 3 INO-VATE trial revealed that patients with relapsed/refractory ALL who received inotuzumab ozogamicin were less likely to receive subsequent salvage therapy than those who received standard...
True or False: Findings from the phase 3 INO-VATE trial revealed that patients with relapsed/refractory ALL who received inotuzumab ozogamicin were less likely to receive subsequent salvage therapy than those who received standard...
True or False: Findings from the...
08/05/2022
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use